INTRODUCTION
Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma accounting approximately 3-10% of lymphoma diagnoses. 1 About 2.5-7%
of all Non-Hodgkin lymphoma cases are mantle cell and despite being a low-grade lymphoma, it has the worst prognosis among all lymphomas.
It tends to occur in older adults with a median age of approximately 60 years and is common in males (M: F-2-7:1). 2, 3 Primary gastric mantle cell lymphoma is an extremely rare form of gastrointestinal tumor and represents 2.5-7%of all non-Hodgkin's lymphomas. 4 In the present report, we describe the clinicopathologic features of a case of early primary gastrointestinal mantle cell lymphoma found incidentally on routine
Computed Tomography (CT) scan following pneumothorax.
CASE REPORT
A 69-year-old male with a past medical history of gastroesophageal reflux He subsequently recovered and afollow up PET/CT showed no evidence of lymphoma and his bone marrow biopsy was negative for residual or recurrent disease.
DISCUSSION
The genetic hallmark of mantle cell lymphoma is the chromosomal translocation t(11;14)(q13;q32) which leads to the deregulation and upregulation of Cyclin D1 which is an important regulator of the G1 phase of the cell cycle. 5 Cyclin D1 plays an important role in the cell cycle regulation G1-S transition following mitotic growth factor signaling.
Cyclin D1 binds to CDK4 and CDK6 to form a CDK/cyclin complex able to phosphorylate the tumor suppressor retinoblastoma (RB1) facilitating cell cycle progression. Thus, cyclin D1 overexpression would contribute to the lymphomagenesis in MCL by overcoming the suppressor effect that retinoblastoma performs in the G1/S transition. can still be false negative, mainly due to the quality of the material. 12 Cell proliferation (Ki-67) has been exploratively analyzed as an important biologic marker and has showed strong additional prognostic relevance.
CCND1 expression, due to the presence of t(11;14)(q13;q32) translocation, is present in virtually all cases of MCL, 12 however, a very few cases that do not express CCND1 might exist. 13 Recently a new prognostic model has been introduced by the German Lymphoma Study Group called the MIPI (MCL International Prognostic Index) on the basis of age, performance status, serum lactate dehydrogenase and leukocyte count. for multiple myeloma is another agent that has been evaluated in MCL alone and in combination. 15 Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) targeting the phospatidyl inositol 3 kinase pathway. 17 This mechanism inhibits the translation of mRNA, including cyclin D1 mRNA, making this agent a sound therapeutic agent in MCL. 
CONCLUSION

